Merck recognised with INTERPHEX Exhibitor Award for Best New Product
10 April 2019 | By Merck
Merck wins award for first-of-its-kind, single-use tangential flow filtration capsule used in ADC and monoclonal antibody bioprocessing...
List view / Grid view
Anti-Cancer Therapeutics
Whitepaper: Analytical criteria in bacterial endotoxin testing using LAL and rFC
21 February 2019 | By Hyglos-bioMerieux
This article covers the analytical criteria that apply to Bacterial Endotoxin Testing (BET) using Limulus Amebocyte Lysate (LAL) or recombinant Horseshoe crab Factor C (rFC) for the bioactivity determination of endotoxin in aqueous solutions, such as pharmaceuticals and medical device extracts. It explains the importance of these criteria for accurate…
FDA approval for leukaemia non-chemo combination therapy
29 January 2019 | By European Pharmaceutical Review
The FDA has approved the first ever non-chemotherapy combination treatment using ibrutinib and obinutuzumab for the most common form of adult leukaemia...
Cancer drug with accelerated approval fails Phase III trial
22 January 2019 | By Nikki Withers (European Pharmaceutical Review)
Results did not confirm the clinical benefit of Lartruvo in combination with doxorubicin compared to doxorubicin alone…
European Commission approves prostate cancer treatment Erleada
18 January 2019 | By Nikki Withers (European Pharmaceutical Review)
Erleada (apalutamide) has been approved for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
Almac Group extends personalised cancer vaccine production facilities
18 January 2019 | By Almac Group
The Almac Group, a CDMO serving the pharmaceutical and biotech sectors globally, is expanding its Edinburgh Technopole facility to allow scale-up of its personalised cancer vaccine activities...
Durvalumab improves survival of non-small cell lung cancer patients
28 September 2018 | By Iqra Farooq (European Pharmaceutical Review)
Moffitt researchers conducted a Phase III trial which found durvalumab to increase the survival of patients with non-small cell lung cancer...
Pioneering radiotherapy machine treats its first patient in the UK
26 September 2018 | By Mike Stones
Improved accuracy and fewer patient side effects are among the benefits claimed for the pioneering radiotherapy machine...
New micro-platform improves understanding of cancer cells
21 September 2018 | By Mike Stones
A new low-cost, cell culture platform technique may provide insight for more effective cancer treatment, according to the researchers who developed it...
Cardiac monitoring for high-risk breast cancer patients ‘should be prioritised’
8 August 2018 | By Mike Stones
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
Senescent cells targeted with new nanocarrier drug delivery system
6 August 2018 | By Mike Stones
Senescent, or zombie cells, are being targeted with the development of a new nanocarrier drug delivery system.
Anti-PD-1 therapy linked to delayed onset of skin disease
20 July 2018 | By Iqra Farooq (European Pharmaceutical Review)
The onset of side effects of a common cancer treatment, anti-PD-1 therapy can be identified up to 3 years after treatment...
Blood test predicts treatment response for metastatic prostate cancer
2 July 2018 | By European Pharmaceutical Review
Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy...
Phenformin-mTOR inhibitor combination shows promise in HCC
28 June 2018 | By European Pharmaceutical Review
A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival...
SMC approves Xermelo for carcinoid syndrome diarrhoea
13 June 2018 | By European Pharmaceutical Review
Scotland is the first country in the UK to enable patients, battling this serious and debilitating condition, access to a new treatment option...
Follow: